Stay updated on Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Sign up to get notified when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.

Latest updates to the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page
- Check4 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing Revision: v3.0.1, and the Back to Top element has been removed. This reflects a simple version bump and a minor UI tweak with no changes to core content or key data.SummaryDifference0.6%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.6%
- Check18 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location details, as well as multiple updates to study statuses and outcome measures. Notably, several location-related terms have been removed.SummaryDifference45%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.3%
- Check48 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference4%
Stay in the know with updates to Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.